Minerva Neurosciences (NERV) Free Cash Flow (2013 - 2026)

Minerva Neurosciences has reported Free Cash Flow for 14 years, with the latest figure at -$5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 32.61% year-over-year to -$5.4 million; the trailing twelve-month figure through Mar 2026 stood at -$14.8 million (up 15.34% YoY), and the FY2025 full-year result was -$13.5 million, up 30.89% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$5.4 million, down from -$4.5 million in the prior quarter.
• The five-year high for Free Cash Flow was -$115407.0 in Q1 2023, with the low at -$9.5 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$4.6 million across 5 years, with a median of -$4.5 million in 2025.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 98.01% — and 2024, when it slumped 5180.68%.
• Minerva Neurosciences' Free Cash Flow stood at -$4.1 million in 2022, then slumped by 45.77% to -$6.0 million in 2023, then grew by 13.76% to -$5.2 million in 2024, then climbed by 12.69% to -$4.5 million in 2025, then slipped by 19.71% to -$5.4 million in 2026.
• The last three Free Cash Flow figures came in at -$5.4 million (Q1 2026), -$4.5 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.